Aflibercept ameliorates retinal pericyte loss and restores perfusion in streptozotocin-induced diabetic mice
Open Access
- 19 October 2020
- journal article
- research article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 8 (1) , e001278
Abstract
Introduction Anti-vascular endothelial growth factor (VEGF) agents are used worldwide for advanced-stage diabetic retinopathy (DR). In contrast, apart from blood glucose control, there are no specific treatments that can limit the progression of early-stage DR that starts with pericyte loss and the destruction of the blood–retinal barrier. Here, we examined the efficacy of aflibercept, a potent anti-VEGF agent, against early-DR pathologies in a murine model of streptozotocin (STZ)-induced DR. Research design and methods STZ was intraperitoneally administered in 8-week-old C57BL/6N male mice. After 4 weeks, the mice were divided into aflibercept-treated and saline-treated groups. Eight weeks after the STZ injection, vascular permeability/leakage was measured with fluorescein angiography in live mice. At 4, 6, and 8 weeks after the STZ injection, the eyes were enucleated, flat-mounted, and stained for platelet-derived growth factor receptor-β to assess pericyte abundance, CD45 to assess leukocyte recruitment, and fluorescein isothiocyanate dextran to assess perfusion. VEGF levels were quantified in each group. The effects of aflibercept on pericyte number, perfusion status, and leukocyte recruitment/accumulation on mice with diabetes retina were evaluated. Results Our murine model successfully replicated the salient pathologies of DR such as pericytes loss, hyperpermeability, and perfusion blockage. Interestingly, numerous leukocytes and leukocyte clumps were found in diabetic retinal capillaries, especially in the non-perfused border area of the retina, suggesting a possible mechanism for non-perfusion and related pericyte damage. Treatment with aflibercept in mice with diabetes inhibited the upregulation of VEGF and the associated adhesion molecules while reducing the defects in perfusion. Aflibercept also attenuated pericyte loss in the diabetic retina. Conclusion VEGF inhibition through aflibercept treatment decreased leukocyte recruitment and aggregation, perfusion blockage, retinal hypoperfusion, and hyperpermeability in mice with diabetes and ultimately attenuated pericyte loss. Our findings suggest that anti-VEGF strategies may prove useful as possible therapies for limiting the progression of early-stage DR.Keywords
Funding Information
- National Research Foundation of Korea (2017R1D1A1B05028221, NRF-2017M3C7A1028949)
- Bayer HealthCare (IIR-KR-2017-4533)
This publication has 55 references indexed in Scilit:
- Animal Models of Diabetic Retinopathy: Summary and ComparisonJournal of Diabetes Research, 2013
- Pathophysiology and treatment of diabetic retinopathyActa Diabetologica, 2013
- Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor modelsAngiogenesis, 2012
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- VEGFR1–mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathyProceedings of the National Academy of Sciences, 2009
- Aflibercept in Epithelial Ovarian CarcinomaFuture Oncology, 2009
- A role for VEGF as a negative regulator of pericyte function and vessel maturationNature, 2008
- VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockadeProceedings of the National Academy of Sciences, 2007
- Retinal OxygenArchives of Ophthalmology (1950), 2003